Skip to main content

Table 2 Patients characteristics

From: “Fighting an uphill battle”: experience with the HCV triple therapy: a qualitative thematic analysis

Variable   Patients (n = 13)
HCV Genotype 1   13 (100%)
Fibrosis stage 0-1   1 (8%)
Fibrosis stage 2   3 (23%)
Fibrosis stage 3   3 (23%)
Fibrosis stage 4   6 (46%)
Gender Male 8 (62%)
  Female 5 (38%)
Mean age in years (range)   49 (36–63)
Transmission IDU1 6 (46%)
  Blood products 2 (15%)
  Unsafe sex 1 (8%)
  Unsafe tattooing 1 (8%)
  Unknown 3 (23%)
Opioid substitution   3 (23%)
Multimorbidity2   4 (30%)
First diagnosed mean years (range)   12.5 (1.5 - 28)
Treatment experience Naive 5 (38%)
  Dual therapy 1× 7 (54%)
  Dual therapy 2× 1 (8%)
Protease inhibitor Telaprevir 9 (70%)
  Boceprevir 4 (30%)
Status proteaseinhibitor therapy Ongoing 5 (38%)
Completed 5 (38%)
Discontinued3 3 (23%)
Residence situation With Partner/Family 8 (62%)
  alone 3 (23%)
  Institution4 2 (15%)
Occupation before triple therapy   10 (80%)
Job related working ability during triple therapy 0-25% 5 (50%)
  26-50% 1 (10%)
  51-75% 1 (10%)
  76-100% 3 (30%)
  1. 1Intravenous drug user.
  2. 2One patient with HIV, haemophilia, Depression or Schizophrenia.
  3. 3Two patients due to neutropenia, one patient due to unbearable side effects.
  4. 4Mental hospital, assisted accommodation.